Rituximab is Effective for the quality of life of children w
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Rituximab (RTX) is an effective treatment to maintaining remission in patients with nephrotic syndrome (NS), but there are few reports on the effect of RTX treatment on quality of life (QOL). The purpose of this study was to examine the effect of a periodically repeated RTX treatment from the perspective of QOL.

Via a two-year RTX treatment regimen, researchers systematically measured the QOL of pediatric patients with refractory NS, as well as parent's views of their child's QOL. Patients with refractory NS in children who met certain requirements were enrolled. RTX infusions were given four times at six-month intervals, then mizoribine was given, and calcineurin inhibitors were stopped early. PedsQL was used to assess QOL at each RTX administration, and the results were reviewed two years later.

A total of 22 patients were examined. Over the course of two-year recovery program, both the patient's QOL and their parent's views of their QOL changed. Nonetheless, on all scales, the parent's ratings were lower than the patient's, with slower development.

In conclusion, this treatment procedure improved QOL significantly in patients with refractory NS. Although there are risks associated with RTX therapy, it is beneficial for patients with refractory NS.

Source: https://onlinelibrary.wiley.com/doi/10.1111/ped.14725?af=R
Like
Comment
Share